Ionis to Present New Olezarsen Data Ahead of FDA Decision

Event summary

  • Ionis will present new analyses from CORE and CORE2 Phase 3 studies of olezarsen at three medical congresses in June 2026.
  • Olezarsen demonstrated significant triglyceride reduction and pancreatitis risk reduction in prior studies.
  • FDA Priority Review for olezarsen has a target action date of June 30, 2026.
  • Four oral presentations will cover different patient subgroups and treatment backgrounds.

The big picture

Ionis is positioning olezarsen as a potential breakthrough for severe hypertriglyceridemia, a condition with limited treatment options. The upcoming data presentations come at a critical juncture ahead of the FDA's decision, highlighting the strategic importance of demonstrating olezarsen's efficacy across diverse patient populations. The focus on pancreatitis prevention aligns with growing recognition of this debilitating complication in cardiovascular disease management.

What we're watching

Regulatory Approval
Whether the FDA will approve olezarsen by the June 30, 2026 target date based on the presented data.
Clinical Differentiation
How the new analyses will position olezarsen against existing therapies for severe hypertriglyceridemia.
Market Potential
The pace at which Ionis can commercialize olezarsen if approved, given the unmet need in sHTG.